Bio Path reported $488K in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Alterity Therapeutics Limited AUD 8.67M 893.38K Dec/2025
Baxter International USD 3.19B 554.4M Dec/2025
Bio Path USD 488K 4.07M Sep/2025
Cipla INR 60.98B 1.06B Dec/2025
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 11.29M 1.51M Dec/2025
CSL USD 5.7B 2.82B Dec/2025
Grifols EUR 1.99B 217.4M Dec/2025
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025